R&D News | pharmaphorum

News

Halda Therapeutics' president and chief executive, Christian Schade

J&J swoops on cancer biotech Halda with $3bn takeover deal

Johnson & Johnson has added to the flurry of M&A deals in pharma with an agreement to buy Halda Therapeutics and its RIPTAC anticancer platform.

News

BMS, J&J give up on milvexian for acute coronary syndrome

BMS and J&J call time on oral anticoagulant milvexian in acute coronary syndrome, but are still running trials in atrial fibrillation and stroke.

News

Sofinnova Partners raises €650m for early-stage biotechs

European life sciences venture capital company Sofinnova Partners has closed its latest fund, Sofinnova Capital XI, raising €650 million.

News

Lundbeck makes bid for Avadel, trying to displace Alkermes

Another pharma M&A fight has broken out, with Lundbeck outbidding Alkermes in an attempt to take control of Avadel Pharma and its narcolepsy product.

News

Medicxi raises €500m for latest biotech fund

Medicxi closes its fifth round, raising €500m for 'asset-centric' firms at all stages of development and taking the total raised in 10 years to €2bn+.

News

Update: MSD's $9.2bn deal for flu biotech Cidara confirmed

MSD has signed a $9.2 billion takeover deal for Cidara that will bolt on a universal flu prevention candidate in phase 3.

J&J swoops on cancer biotech Halda with $3bn takeover deal

BMS, J&J give up on milvexian for acute coronary syndrome

Sofinnova Partners raises €650m for early-stage biotechs

Lundbeck makes bid for Avadel, trying to displace Alkermes

Medicxi raises €500m for latest biotech fund

Update: MSD's $9.2bn deal for flu biotech Cidara confirmed

AI, start-ups, and the future of human health: AION Labs’ Ma...

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks